Clinical Trials

NCT01958918 SALT, Phase IV
Status: completed
A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg Ranibizumab PRN versus 2 mg Aflibercept bimonthly intravitreal injections on central retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular AMD.

NCT01594281 PRIDE, Phase II
Status: completed
Multicenter randomized open-label three-arms controlled 12 months clinical Proof of Concept Study to evaluate efficacy and safety of Ranibizumab alone or in combination with Laser Photocoagulation vs. Laser Photocoagulation alone in Proliferative Diabetic Retinopathy.

NCT02194803 ORCA, Observational Study
Status: completed
Observation of Treatment Patterns with Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in approved indications Collaboration with GRADE (Bonn) and M3 (Münster).

NCT01131585 RELATION, Phase IIIb
Status: completed
A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of Laser Photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. Laser Photocoagulation monotherapy in patients with Visual Impairment due to Diabetic Macular Edema followed by a 12 month follow up period.

NCT02257632 TIDE AMD, Phase IV
Status: completed
A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF Protein Dynamics following monthly intravitreal injections of 0.5 mg Ranibizumab versus 2 mg Aflibercept until study week 12 in patients with Neovascular (Wet) Age-related Macular Degeneration.

NCT02258009 TIDE DME, Phase IV
Status: withdrawn
A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF Protein Dynamics following monthly intravitreal injections of 0.5 mg Ranibizumab versus 2 mg Aflibercept until study week 12 in patients with Visual Impairment due to Diabetic Macular Edema.

Nach oben scrollen